Spots Global Cancer Trial Database for Phase II Study of Bexarotene in Patients With Acute Myeloid Leukemia
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: Phase II Study of Bexarotene in Patients With Acute Myeloid Leukemia
Official Title: A Phase II Study of Bexarotene in Patients With Acute Myeloid Leukemia
Study ID: NCT00615784
Conditions
Interventions
Study Description
Brief Summary: The purpose of this study is to evaluate the activity of bexarotene, a retinoic acid class drug, in patients with Acute Myeloid Leukemia (AML) that has returned after or is resistant to standard chemotherapy or are otherwise not eligible for conventional chemotherapy. Retinoic acids are a class of drugs related to Vitamin A, and have a wide range of effects within normal and malignant cells that affect cell growth and cell death.
Detailed Description:
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
Abramson Cancer Center of University of Pennsylvania, Philadelphia, Pennsylvania, United States
Contact Details
Name: Donald E. Tsai, MD, PhD
Affiliation: University of Pennsylvania
Role: PRINCIPAL_INVESTIGATOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
